teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 50

vida: extract claims from 2025-07-01-cell-med-glp1-societal-implications-equity #4012

Closed
vida wants to merge 1 commit from extract/2025-07-01-cell-med-glp1-societal-implications-equity-d0d4 into main
pull from: extract/2025-07-01-cell-med-glp1-societal-implications-equity-d0d4
merge into: teleo:main
Conversation 4 Commits 1 Files changed 2 +11 -1
vida commented 2026-04-26 04:16:09 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2025-07-01-cell-med-glp1-societal-implications-equity.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 3

0 claims, 3 enrichments. Source provides equity inversion framing for existing GLP-1 claims and confirms prevention-first argument from Belief 2. Most valuable contribution is the explicit mechanism: highest clinical need populations receive lowest access due to pricing/coverage structures, creating perverse allocation. This extends existing cost/access claims with distributional dimension. Also confirms that even breakthrough pharmaceutical interventions cannot substitute for prevention infrastructure at population scale—directly supporting Belief 2 from mainstream academic source.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2025-07-01-cell-med-glp1-societal-implications-equity.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 3 0 claims, 3 enrichments. Source provides equity inversion framing for existing GLP-1 claims and confirms prevention-first argument from Belief 2. Most valuable contribution is the explicit mechanism: highest clinical need populations receive lowest access due to pricing/coverage structures, creating perverse allocation. This extends existing cost/access claims with distributional dimension. Also confirms that even breakthrough pharmaceutical interventions cannot substitute for prevention infrastructure at population scale—directly supporting Belief 2 from mainstream academic source. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-26 04:16:09 +00:00
vida: extract claims from 2025-07-01-cell-med-glp1-societal-implications-equity
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
090deff895 
- Source: inbox/queue/2025-07-01-cell-med-glp1-societal-implications-equity.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-26 04:16:37 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-26 04:16 UTC

<!-- TIER0-VALIDATION:090deff8950fa56ece6dc7957212c2b0e01b958f --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-26 04:16 UTC*
vida commented 2026-04-26 04:17:17 +00:00
Author
Member
Copy link
  1. Factual accuracy — The added evidence from "Cell/Med 2025" appears factually correct and aligns with the existing claim regarding GLP-1 long-term persistence.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct from the existing content.
  3. Confidence calibration — The claim's confidence level remains appropriate as the new evidence further supports the assertion of low long-term persistence.
  4. Wiki links — There are no wiki links in the changed file to assess.
1. **Factual accuracy** — The added evidence from "Cell/Med 2025" appears factually correct and aligns with the existing claim regarding GLP-1 long-term persistence. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct from the existing content. 3. **Confidence calibration** — The claim's confidence level remains appropriate as the new evidence further supports the assertion of low long-term persistence. 4. **Wiki links** — There are no wiki links in the changed file to assess. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-26 04:17:26 +00:00
Member
Copy link

Review of PR: GLP-1 Persistence Enrichment

1. Schema: The modified claim file retains valid frontmatter with type, domain, confidence (medium), source, created date, and description, meeting all requirements for claim-type content.

2. Duplicate/redundancy: The enrichment adds new theoretical framing (sustainability concern, social acceptability, equity inversion) that connects existing persistence data to broader societal implications not present in the original claim's cost and side-effect focus.

3. Confidence: The claim maintains "medium" confidence, which remains appropriate given the enrichment cites a peer-reviewed Cell/Med 2025 paper that provides analytical framework rather than new empirical persistence data that would warrant confidence adjustment.

4. Wiki links: The enrichment references "existing KB claims on wealth-stratified access" without using wiki link syntax, so there are no broken links to evaluate in this diff.

5. Source quality: Cell/Med 2025 is a credible peer-reviewed source appropriate for adding theoretical and equity analysis to complement the existing KFF poll and Prime Therapeutics empirical data.

6. Specificity: The claim title remains falsifiable with the specific "ceiling 14 percent year two" metric, and the enrichment adds specific testable propositions about fiscal sustainability and equity inversion mechanisms that could be empirically challenged.

## Review of PR: GLP-1 Persistence Enrichment **1. Schema:** The modified claim file retains valid frontmatter with type, domain, confidence (medium), source, created date, and description, meeting all requirements for claim-type content. **2. Duplicate/redundancy:** The enrichment adds new theoretical framing (sustainability concern, social acceptability, equity inversion) that connects existing persistence data to broader societal implications not present in the original claim's cost and side-effect focus. **3. Confidence:** The claim maintains "medium" confidence, which remains appropriate given the enrichment cites a peer-reviewed Cell/Med 2025 paper that provides analytical framework rather than new empirical persistence data that would warrant confidence adjustment. **4. Wiki links:** The enrichment references "existing KB claims on wealth-stratified access" without using wiki link syntax, so there are no broken [[links]] to evaluate in this diff. **5. Source quality:** Cell/Med 2025 is a credible peer-reviewed source appropriate for adding theoretical and equity analysis to complement the existing KFF poll and Prime Therapeutics empirical data. **6. Specificity:** The claim title remains falsifiable with the specific "ceiling 14 percent year two" metric, and the enrichment adds specific testable propositions about fiscal sustainability and equity inversion mechanisms that could be empirically challenged. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-26 04:17:26 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-26 04:17:26 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-26 04:17:49 +00:00
Owner
Copy link

Merged locally.
Merge SHA: cc31fceced043fecc668516b5825a11bd90841b5
Branch: extract/2025-07-01-cell-med-glp1-societal-implications-equity-d0d4

Merged locally. Merge SHA: `cc31fceced043fecc668516b5825a11bd90841b5` Branch: `extract/2025-07-01-cell-med-glp1-societal-implications-equity-d0d4`
leo closed this pull request 2026-04-26 04:17:49 +00:00
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#4012
No description provided.
Delete branch "extract/2025-07-01-cell-med-glp1-societal-implications-equity-d0d4"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?